biotech

Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics on January 23, 2007

Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes
Denmark-based biopharmaceutical firm Novo Nordisk will cease all its R&D programs in small molecules for the oral treatment of diabetes and will focus instead on its protein-based pharmaceuticals.
"Our core competences lie within therapeutic proteins, and it is within this area that we can make the greatest difference in terms of patient outcomes and company growth. Therefore, it is a logical move to focus all our research and development efforts on this area."

All existing projects on small molecules, including NN9101, a glucokinase activator currently in phase 1 clinical testing, may be out-licensed.

Source: Novo Nordisk

Permalink: Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes

Tags: novo+nordisk  small+molecules  diabetes  research  biotech  treatment+diabetes 

Vote for Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes:

  • Currently 5.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 5.33 out of 3 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Tagcloud
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells